HB 2204
In CommitteeHouse
Health technology assessment
Concerning the health technology assessment program.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill updates Washington’s health technology assessment program to improve how the state evaluates new medical devices, drugs, or procedures for coverage in state health programs. It strengthens evidence-based review standards, adds transparency and public input, and requires faster decision timelines—especially for rare or life-threatening conditions. The goal is to ensure coverage decisions reflect the best available science while protecting patient access and managing costs.
- The state will review up to six health technologies in the first year and up to eight in the second year after the bill takes effect, with priority given to technologies used in Medicare, recommended in national guidelines, or with high state costs or safety/efficacy concerns.
- Covered technologies must be re-reviewed at least every 18 months, and earlier if new evidence emerges—considering only new evidence combined with prior findings.
- The public or interested parties (e.g., patient groups, providers) can petition the committee to review specific technologies not yet selected by the administrator.
- Assessments must be done by federally designated evidence-based centers and must weigh the most reliable evidence, while also considering impacts on specific populations (e.g., by race, age, disability).
- For life-threatening or rare diseases, the committee must review all available clinical trials—even if randomized trials are unethical or impractical—and may consider expert input instead.
- The committee must make a coverage decision (including medical necessity criteria) within 180 days of submission, publish decisions publicly, and provide written explanations for adverse rulings.
Who is affected
- Patients and their families — Patients who may gain or lose access to certain medical technologies depending on whether they are covered by state health programs, especially those with life-threatening or rare conditions.
- State health care agencies (e.g., Health Care Authority) — State agencies that run health care programs (e.g., Medicaid, state employee health plans) must follow the committee’s coverage decisions and criteria for using new technologies.
- Health care providers — Hospitals, clinics, and providers who use or plan to use the technologies covered by the program must adhere to new coverage rules and medical necessity criteria.
- Medical technology companies — Technology manufacturers and developers may need to submit evidence or respond to requests for data, and may see changes in market access based on state coverage decisions.
- Patient advocacy groups and interested parties — Patients, advocates, and organizations that submit petitions or public comments to influence which technologies are reviewed or how they are covered.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
The bill explicitly allows use of non-randomized evidence and expert input for life-threatening or rare diseases—expanding access to technologies where RCTs are unethical or impractical—directly benefiting patients with conditions like certain cancers, neurodegenerative diseases, or ultra-rare genetic disorders.
HealthcarePeopleRef: Sec. 1(5); Sec. 2(1)(a)Petition-based review and mandatory public comment create a formal channel for patient advocacy groups and providers to influence coverage decisions—empowering marginalized communities and rare-disease patients to advocate for technologies otherwise deprioritized by the state.
HealthcarePeopleRef: Sec. 1(3); Sec. 2(2)(b)Mandating that assessments give greatest weight to the most valid and reliable evidence (e.g., systematic reviews, high-quality RCTs) and consider real-world data from state agencies improves the scientific rigor of coverage decisions—reducing coverage of low-value or harmful technologies and improving patient outcomes.
HealthcarePeopleRef: Sec. 1(4)(d)(i); Sec. 2(1)(a)The 180-day decision deadline and requirement for written explanations for adverse rulings increases transparency and accountability—helping patients and providers anticipate coverage changes and appeal decisions, reducing arbitrary or delayed denials.
HealthcarePeopleRef: Sec. 2(4)Prioritizing technologies already covered under Medicare or recommended in national guidelines creates a more predictable and stable coverage landscape—reducing administrative burden for providers and ensuring Washington aligns with national best practices, benefiting patients who rely on continuity of care.
HealthcareLean peopleRef: Sec. 1(1)(a); Sec. 2(3)
Potential Concerns (5)
The bill prioritizes technologies with high state expenditures for review, which may lead to coverage denials or restrictive medical necessity criteria for expensive but clinically valuable technologies—especially those used for rare conditions—potentially limiting access for patients who rely on state health programs.
HealthcarePeopleRef: Sec. 1(1)(b)(ii)The 18-month rereview cycle and 180-day decision deadline may pressure the committee to make coverage decisions before robust long-term evidence is available—particularly for novel or complex technologies—potentially leading to premature coverage denials or overly restrictive criteria that reduce access.
HealthcarePeopleRef: Sec. 1(2); Sec. 2(4)The requirement for 'adequate evidence available to conduct the complete review' may exclude promising but newer or less-studied technologies (e.g., gene therapies, AI-driven diagnostics) from review, delaying or preventing coverage for patients with rare or complex conditions who lack alternatives.
HealthcareLean peopleRef: Sec. 1(1)(b)(iii)While the bill mandates consideration of impacts on specific populations (e.g., race, disability), it does not require differential coverage standards or additional funding to address disparities—meaning assessments may highlight inequities without changing coverage decisions in favor of underserved groups.
HealthcareLean peopleRef: Sec. 1(4)(d)(ii); Sec. 2(1)(a)The requirement to align coverage decisions with Medicare and national guidelines unless 'substantial evidence' supports deviation may entrench existing (and sometimes outdated or biased) clinical norms, slowing adoption of innovations that could benefit Washington-specific populations.
HealthcareLean peopleRef: Sec. 2(3)
Who Is Most Affected
Patients with life-threatening or rare diseases benefit significantly—especially those whose conditions lack standard-of-care treatments or for whom RCTs are unethical. The bill's flexibility to use non-randomized evidence and expert input directly improves access for this group.
Medicaid and state employee health plan enrollees may benefit from more rigorous, transparent coverage decisions that reduce use of low-value or harmful technologies—but could be harmed if expensive but effective treatments are excluded due to cost concerns or evidence thresholds.
Hospitals and clinics may benefit from clearer medical necessity criteria and reduced administrative burden—but could face challenges if coverage decisions lag behind clinical innovation or restrict reimbursement for newer technologies.
Medical technology companies developing high-cost or novel therapies (e.g., gene therapies, AI diagnostics) may face longer time-to-coverage and more rigorous evidence requirements—potentially reducing short-term market access but improving long-term predictability and credibility of state coverage decisions.
Patient advocacy groups gain formal petition rights and public comment access—strengthening their role in shaping coverage—but must invest resources to submit petitions and evidence, which may favor well-funded national organizations over local grassroots groups.